CMS Administrator Tom Scully today (Oct. 3) told lawmakers that his agency is prepared to take administrative action to remedy's Medicare's average wholesale price (AWP) system, according to Scully's written testimony for today's Ways and Means Subcommittee hearing on AWP.


rs Made By Health Care Professionals

GOP Senators Frist and Jeffords inch closer to supporting bill. Click here for Kennedy Bill Click here for Section-By-Section Analysis


ll

BINGAMAN FLOOR STATEMENT

PASSAGE OF S. 724, THE "MOTHERS AND NEWBORNS

HEALTH INSURANCE ACT OF 2001"

Mr. President, I rise today with the purpose of asking unanimous consent to take up and pass S. 724, the "Mothers and Newborns Health Insurance Act of 2001," as reported by the Senate Finance Committee. This legislation, introduced by Senators Bond and Breaux, would simply give states the option of covering pregnant women in the State Children's Health Insurance Program, or CHIP, for the full range of pre- and postpartum care.


Bill includes provisions for device user fees and establishing a new office of combination products. Click here for AdvaMed Statement Click here for Full Text Of Bill Click here for Summary Of Bill


/index.php?option=com_iwpfile&file=/dir_01/he2002_2551.pdf

/index.php?option=com_iwpfile&file=/dir_01/he2002_2550.pdf

ed

For Immediate Release

Wednesday, Oct. 2, 2002

Grassley, Baucus Bill Language Redirects Money to Uninsured Kids

WASHINGTON -- Medicare legislation from Sens. Max Baucus and Chuck Grassley would prohibit the Department of Health and Human Services from allowing states to divert federal funds that are dedicated to children's health to instead cover childless adults.


/index.php?option=com_iwpfile&file=/dir_01/he2002_2548.pdf

ss Bill

AARP, Rx Health Value and Coalition for a Competitive Pharmaceutical Market say the survey underscores the need for Congress to act now on drug patent reform legislation passed by the Senate.


ce

To: FDA-wide

Re: Establishment of Office of Pediatric Therapeutics

Today I am pleased to announce that on October 1, 2002 the Office of Pediatric Therapeutics (OPT) will be established within the Office of the Commissioner / Office of International Activities and Strategic Initiatives. This office will report to Murray M. Lumpkin, M.D. in his capacity as Senior Associate Commissioner.


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.